Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from PainChek Ltd ( (AU:PCK) ).
PainChek Ltd has applied to the ASX for quotation of 176,471 new fully paid ordinary shares, issued on 22 December 2025 under a previously announced transaction. The modest share issuance expands the company’s quoted capital base and reflects ongoing use of equity to support its corporate or transactional activities, with limited immediate dilution but signalling continued capital management as PainChek advances its digital health technology in the market.
More about PainChek Ltd
PainChek Ltd is an Australian-listed healthcare technology company focused on developing and commercialising digital tools for pain assessment. Its primary product is a medical device software solution that uses smart devices and AI-driven facial analysis to help clinicians and carers objectively assess pain, particularly in people unable to communicate their discomfort, with a key focus on aged care and clinical settings.
Average Trading Volume: 461,214
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$58.47M
See more insights into PCK stock on TipRanks’ Stock Analysis page.